Stocks · News reference
Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones
Disc Medicine says Phase 2 RESTORE-PV data shows DISC-3405 reduces phlebotomy needs and controls hematocrit in polycythemia vera patients.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $86
Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $79 to $86.